The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled out to support accelerated market penetration and expanded reachFocused on unlocking the full market potential of Talicia, the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1, THI and Cumberland will manage the launch and ongoing joint commercialization activitiesH. pylori infection affects 35% of the U.S. adult population and an estimated 1.6 million U.S. patients are treated annually2. Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based H

2/25/26 7:00:00 AM ET

$CPIX

$RDHL

Biotechnology: Pharmaceutical Preparations

Health Care

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

NASHVILLE, Tenn., Feb. 25, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, today announced the launch of its national sales promotional for Talicia®. Cumberland has assumed responsibility for the distribution and sales promotion of the brand in the U.S. under the co-commercialization agreement with RedHill Biopharma. Talicia is an FDA-approved oral capsule indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer. Talicia is the only all-in-one treatment containing omeprazole, amoxicillin and rifabutin and

2/25/26 7:00:00 AM ET

$CPIX

Biotechnology: Pharmaceutical Preparations

Health Care

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

NASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026. A conference call will be held on March 3 at 4:30 p.m. Eastern Time to discuss the results and update.The link to register is https://register-conf.media-server.com/register/BI6effc1a9cae9445f9bb0d60817870ffa.Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at

2/24/26 4:05:00 PM ET

$CPIX

Biotechnology: Pharmaceutical Preparations

Health Care

$CPIX
Financials

Live finance-specific insights

View All

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

2/25/26 7:00:00 AM ET

$CPIX

Biotechnology: Pharmaceutical Preparations

Health Care

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

2/24/26 4:05:00 PM ET

$CPIX

Biotechnology: Pharmaceutical Preparations

Health Care

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

NASHVILLE, Tenn., Feb. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients. The FDA's Fast Track program facilitates the development and expedites the review of a drug designed to treat a serious or life-threatening condition and unmet medical need. This designation provides an opportunity for more frequent communication with the FDA, enabling Cumberland, as the sponsor, to o

2/4/26 9:05:00 AM ET

$CPIX

Biotechnology: Pharmaceutical Preparations

Health Care

Cumberland Pharmaceuticals Said On June 2 FDA Informed Co That It Had Granted A Barrier-to-Innovation Waiver Associated With Reditrex Product Line Which Will Result In Refund Of ~$1.2M Co Paid For Prescription Drug Program Fees For Reditrex Product Line

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CPIX

Cumberland Pharmaceuticals Said On June 2 FDA Informed Co That It Had Granted A Barrier-to-Innovation Waiver Associated With Reditrex Product Line Which Will Result In Refund Of ~$1.2M Co Paid For Prescription Drug Program Fees For Reditrex Product Line

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CPIX

$CPIX
Press Releases

Joint U.S. Commercialization of RedHill's Talicia® Commences

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

$CPIX
Insider Purchases

Director Young Caroline bought $398 worth of shares (121 units at $3.29), increasing direct ownership by 0.37% to 32,942 units (SEC Form 4)

Director Jones James bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.60% to 43,938 units (SEC Form 4)

Chairman and CEO Kazimi A J bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.00% to 5,700,030 units (SEC Form 4)

$CPIX
SEC Filings

SEC Form SCHEDULE 13G filed by Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

$CPIX
Insider Trading

Director Young Caroline increased direct ownership by 0.20% to 33,309 units (SEC Form 4)

Director Jones James increased direct ownership by 0.60% to 45,063 units (SEC Form 4)

Chairman and CEO Kazimi A J increased direct ownership by 0.00% to 5,701,155 units (SEC Form 4)

$CPIX
Financials

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

$CPIX
Leadership Updates

Sitryx appoints Adam Mostafa as Chief Financial Officer

CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

$CPIX
Large Ownership Changes

SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Said On June 2 FDA Informed Co That It Had Granted A Barrier-to-Innovation Waiver Associated With Reditrex Product Line Which Will Result In Refund Of ~$1.2M Co Paid For Prescription Drug Program Fees For Reditrex Product Line

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $CPIX

Cumberland Pharmaceuticals Said On June 2 FDA Informed Co That It Had Granted A Barrier-to-Innovation Waiver Associated With Reditrex Product Line Which Will Result In Refund Of ~$1.2M Co Paid For Prescription Drug Program Fees For Reditrex Product Line

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $CPIX

$CPIX Press Releases

Joint U.S. Commercialization of RedHill's Talicia® Commences

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

$CPIX Insider Purchases

Director Young Caroline bought $398 worth of shares (121 units at $3.29), increasing direct ownership by 0.37% to 32,942 units (SEC Form 4)

Director Jones James bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.60% to 43,938 units (SEC Form 4)

Chairman and CEO Kazimi A J bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.00% to 5,700,030 units (SEC Form 4)

$CPIX SEC Filings

SEC Form SCHEDULE 13G filed by Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

$CPIX Insider Trading

Director Young Caroline increased direct ownership by 0.20% to 33,309 units (SEC Form 4)

Director Jones James increased direct ownership by 0.60% to 45,063 units (SEC Form 4)

Chairman and CEO Kazimi A J increased direct ownership by 0.00% to 5,701,155 units (SEC Form 4)

$CPIX Financials

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

$CPIX Leadership Updates

Sitryx appoints Adam Mostafa as Chief Financial Officer

CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

$CPIX Large Ownership Changes

SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

Recent Analyst Ratings for
$CPIX

Recent Analyst Ratings for
$CPIX

$CPIX
Press Releases

$CPIX
Insider Purchases

$CPIX
SEC Filings

$CPIX
Insider Trading

$CPIX
Financials

$CPIX
Leadership Updates

$CPIX
Large Ownership Changes